Savant Capital LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Savant Capital LLC lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 47.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,137 shares of the pharmaceutical company’s stock after selling 2,868 shares during the period. Savant Capital LLC’s holdings in Vertex Pharmaceuticals were worth $1,397,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of VRTX. Advisor OS LLC lifted its position in Vertex Pharmaceuticals by 4.4% in the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock valued at $263,000 after purchasing an additional 23 shares during the last quarter. Costello Asset Management INC boosted its position in Vertex Pharmaceuticals by 3.6% during the 2nd quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company’s stock valued at $307,000 after buying an additional 24 shares during the period. Kovack Advisors Inc. grew its holdings in Vertex Pharmaceuticals by 1.9% in the 2nd quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock worth $570,000 after acquiring an additional 24 shares during the last quarter. Newman Dignan & Sheerar Inc. increased its position in shares of Vertex Pharmaceuticals by 3.3% in the second quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock valued at $350,000 after acquiring an additional 25 shares during the period. Finally, Eastern Bank increased its position in shares of Vertex Pharmaceuticals by 1.6% in the second quarter. Eastern Bank now owns 1,635 shares of the pharmaceutical company’s stock valued at $728,000 after acquiring an additional 25 shares during the period. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.2%

Shares of NASDAQ:VRTX opened at $434.19 on Thursday. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68. The stock has a market capitalization of $110.16 billion, a price-to-earnings ratio of 31.04 and a beta of 0.36. The stock has a fifty day simple moving average of $406.47 and a two-hundred day simple moving average of $428.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating the consensus estimate of $4.58 by $0.22. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company’s revenue was up 11.0% on a year-over-year basis. During the same period last year, the company earned $4.38 earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Citigroup raised their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Stifel Nicolaus cut their price objective on Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating on the stock in a research report on Tuesday, November 4th. Leerink Partnrs upgraded Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. Scotiabank cut their price target on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. Finally, Guggenheim reduced their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $489.10.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.